Supervised Treatment Interruptions Fail to Control HIV-1 Viremia.

Supervised Treatment Interruptions Fail to Control HIV-1 Viremia.

Bibliographic Details
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2004-11-01
Series:	PLoS Medicine
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC524379/?tool=EBI

Similar Items

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
by: Hadega A Aamer, et al.
Published: (2020-08-01)

Reconsidering early HIV treatment and supervised treatment interruptions.
by: Richard A Koup
Published: (2004-11-01)

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
by: Oxenius, A, et al.
Published: (2002)

Gut microbiome signatures linked to HIV-1 reservoir size and viremia control
by: Alessandra Borgognone, et al.
Published: (2022-04-01)

Immunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil
by: Samara Tatielle M. Gomes, et al.
Published: (2017-06-01)

Residual Viremia in Treated HIV+ Individuals.
by: Jessica M Conway, et al.
Published: (2016-01-01)

Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms
by: Jana L. Jacobs, et al.
Published: (2019-10-01)

OA3-5 LB Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals initiating ART during acute HIV infection
by: E. Kroon, et al.
Published: (2016-07-01)

Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.
by: Joos, B, et al.
Published: (2005)

Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART
by: Veronica Obregon-Perko, et al.
Published: (2021-12-01)

Nonsuppressible viremia during HIV-1 therapy meets molecular virology
by: Ann Emery, et al.
Published: (2023-03-01)

HIV Viremia Is Associated With APOL1 Variants and Reduced JC-Viruria
by: Etty Kruzel-Davila, et al.
Published: (2021-08-01)

Workflow Interruptions and Failed Action Regulation in Surgery Personnel
by: Achim Elfering, et al.
Published: (2014-03-01)

Treatment Interruptions in Chronic HIV Infection.
Published: (2004-12-01)

Treatment interruption in chronic HIV-1 infection: does it deliver?
by: Willberg, C, et al.
Published: (2007)

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection.
by: Goonetilleke, N, et al.
Published: (2009)

Disparate associations of HLA class I markers with HIV-1 acquisition and control of viremia in an African population.
by: Wei Song, et al.
Published: (2011-01-01)

Bocavirus viremia
by: Pathoom Sukkaromdee, et al.
Published: (2015-01-01)

Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain
by: Llibre JM, et al.
Published: (2013-05-01)

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
by: Josep M Llibre, et al.
Published: (2015-01-01)

Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection
by: Leligdowicz, A, et al.
Published: (2007)

Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection.
by: Leligdowicz, A, et al.
Published: (2007)

Robust gag-specific T cell responses characterize viremia control in HIV-2 infection
by: Leligdowicz, A, et al.
Published: (2007)

HIV viremia is the product of a small fraction of infected cells
by: E. Anderson, et al.
Published: (2017-12-01)

A case report of HIV-1 superinfection in an HIV controller leading to loss of viremia control: a retrospective of 10 years of follow-up
by: Diogo Gama Caetano, et al.
Published: (2019-07-01)

Automated high-throughput quantification of persistent HIV-1 plasma viremia in individuals on ART
by: J. Jacobs, et al.
Published: (2019-12-01)

Antiretroviral Treatment-Induced Galectin-9 Might Impact HIV Viremia in Addition to Contributing to Inflammaging
by: Ashwini Shete, et al.
Published: (2023-07-01)

Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans
by: Azwidowi Lukhwareni, et al.
Published: (2020-06-01)

Limiting cumulative HIV viremia copy years by early treatment reduces risk of AIDS and death
by: Olson, A, et al.
Published: (2016)

Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy
by: Leonardo Weissmann, et al.
Published: (2019-11-01)

Association of low level viremia with inflammation and mortality in HIV-infected adults.
by: Abigail Eastburn, et al.
Published: (2011-01-01)

Factors associated with viremia in people living with HIV on antiretroviral therapy in Guatemala
by: Dean W. Ortíz, et al.
Published: (2021-10-01)

Antiretroviral therapy interruptions: impact on HIV treatment and transmission
by: Dubrocq G, et al.
Published: (2018-06-01)

Evaluation of HIV-specific T-cell responses in HIV-infected older patients with controlled viremia on long-term antiretroviral therapy.
by: Nicole E Behrens, et al.
Published: (2020-01-01)

Evaluation of HIV-specific T-cell responses in HIV-infected older patients with controlled viremia on long-term antiretroviral therapy
by: Nicole E. Behrens, et al.
Published: (2020-01-01)

Researching of resistance to etravirine in some HIV-1 low-level viremia strains by in-silico methods
by: Oflaz Ofcan, et al.
Published: (2023-08-01)

OP 1.3 – 00017 The fraction of cells with unspliced HIV RNA is not associated with plasma viremia
by: A. Capoferri, et al.
Published: (2022-12-01)

Episodes of Guillain-Barré syndrome associated with the acute phase of HIV-1 infection and with recurrence of viremia
by: Castro Gleusa de, et al.
Published: (2006-01-01)

The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?
by: Alessandra Amendola, et al.
Published: (2020-01-01)

HIV-1 viremia during the first 28 weeks of pregnancy is not associated with mother-to-child transmission
by: J.F. Senise, et al.